Tibet Duo Rui Pharmaceutical Co., Ltd. (SHE:301075)

Market Cap	5.89B +246.4%
Revenue (ttm)	137.16M -43.0%
Net Income	-100.54M
EPS	-1.27
Shares Out	78.96M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,614,700
Open	77.62
Previous Close	77.14
Day's Range	73.85 - 80.89
52-Week Range	25.34 - 98.29
Beta	0.65
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 25, 2026

About SHE:301075

Tibet Duo Rui Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of chemical pharmaceutical preparations, intermediates, and raw materials in China. It offers fluid therapy, anesthesiology medication, analgesic medication, and first-aid medication products, as well as sodium acetate ringer's injection; and agent products, such as amoxicillin sodium and clavulanate potassium for injection, etc. The company was founded in 2005 and is headquartered in Tibet, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2005
• Employees: 497
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301075

Financial Performance

In 2025, SHE:301075's revenue was 154.18 million, a decrease of -35.93% compared to the previous year's 240.63 million. Losses were -102.17 million, 63.0% more than in 2024.